Lymphatic and Systemic Immunity Changes in Post-radiation Lymphedema Development
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to find out which immune molecules, cells, and genes are involved
in the development of lymphedema (LE), so that medicines that target them can be considered
for treating lymphedema. The hypothesis is that LE is a systemic, autoimmune-like disease
that is initiated by inflammatory cytokines induced by surgery, radiation, and possibly
chemotherapy in genetically susceptible patients.
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborators:
M.D. Anderson Cancer Center National Cancer Institute (NCI)